A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
Public ClinicalTrials.gov record NCT06855160. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age
Study identification
- NCT ID
- NCT06855160
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 900 participants
Conditions and interventions
Conditions
Interventions
- Candidate varicella vaccine Biological
- Hepatitis A vaccine Biological
- MMR vaccine Biological
- Marketed varicella vaccine Biological
- PCV (pneumococcal conjugate vaccine) 13 Biological
- PCV 20 Biological
- Vaxneuvance Biological
Biological
Eligibility (public fields only)
- Age range
- 12 Months to 15 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 16, 2025
- Primary completion
- Sep 9, 2026
- Completion
- Feb 1, 2027
- Last update posted
- Dec 3, 2025
2025 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Tucson | Arizona | 85704 | Recruiting |
| GSK Investigational Site | Huntington Park | California | 90255 | Recruiting |
| GSK Investigational Site | Sherman Oaks | California | 91403 | Recruiting |
| GSK Investigational Site | Coral Gables | Florida | 33134 | Recruiting |
| GSK Investigational Site | Miami Lakes | Florida | 33014 | Recruiting |
| GSK Investigational Site | Tampa | Florida | 33612 | Recruiting |
| GSK Investigational Site | Idaho Falls | Idaho | 83404 | Recruiting |
| GSK Investigational Site | Dayton | Ohio | 45414 | Recruiting |
| GSK Investigational Site | Houston | Texas | 77584 | Recruiting |
| GSK Investigational Site | Lewisville | Texas | 75067 | Recruiting |
| GSK Investigational Site | Pharr | Texas | 78577 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06855160, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06855160 live on ClinicalTrials.gov.